Pharmaceuticals Canada

Canada Dengue Vaccines Market Analysis, 2024–2034

Canada Dengue Vaccines Market Industry Trends and Forecast to 2034: Segmented by (Product, Age, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Canada · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $47.1 Mn Estimated value
Estimate 2025 $56.5 Mn 7.9% of the global market
Projected 2034 $293.9 Mn 419.9% Adds $237.4 Mn over 9 forecast years
CAGR 2025–2034 20.1% Faster than 87% of 180 Pharmaceuticals markets here
Key players 5
  • Canada is 7.85% of the global market.
  • In North America, the largest is US at $289.7 Mn.
  • Fastest growing: Canada (this report) at 20.1% a year.
  • Canada ranks 2nd of 2 by size in North America.

Market size projection

Canada

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$237.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Dengue Vaccines Market market size by year, Canada
YearMarket sizeChange that yearSince 2025
2024 (estimate) $47.1 Mn — —
2025 (base) $56.5 Mn +$9.5 Mn —
2026 (forecast) $67.9 Mn +$11.4 Mn +20.1%
2027 (forecast) $81.6 Mn +$13.6 Mn +44.2%
2028 (forecast) $97.9 Mn +$16.4 Mn +73.2%
2029 (forecast) $117.6 Mn +$19.7 Mn +108.1%
2030 (forecast) $141.3 Mn +$23.6 Mn +149.9%
2031 (forecast) $169.7 Mn +$28.4 Mn +200.1%
2032 (forecast) $203.8 Mn +$34.1 Mn +260.4%
2033 (forecast) $244.7 Mn +$41.0 Mn +332.9%
2034 (forecast) $293.9 Mn +$49.2 Mn +419.9%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $720.0 Mn
  2. North America $378.9 Mn
  3. US $289.7 Mn
  4. Europe $153.8 Mn
  5. APAC $147.1 Mn
  6. Canada (this report) $56.5 Mn
  7. China $55.3 Mn
  8. Japan $39.6 Mn
  9. Latin America $29.0 Mn
  10. Germany $25.1 Mn
  11. Middle East $26.1 Mn
  12. Brazil $20.7 Mn
  13. Italy $18.2 Mn
  14. France $17.6 Mn
  15. UK $17.2 Mn
  16. India $15.1 Mn
  17. Ecuador $14.0 Mn
  18. Africa $12.6 Mn
  19. Mexico $12.2 Mn
  20. Spain $11.7 Mn
  21. Saudi Arabia $11.2 Mn
  22. Australia $8.3 Mn
  23. New Zealand $7.5 Mn
  24. Russia $6.7 Mn
  25. South Africa $4.4 Mn
  26. UAE $4.3 Mn
  27. Egypt $2.2 Mn
  28. Philippines $1.9 Mn
  29. Hong Kong $1.2 Mn
  30. Malaysia $1.2 Mn
  31. Thailand $0.9 Mn
  32. Singapore $0.7 Mn
  33. Kenya $0.6 Mn

The Canada Dengue Vaccines Market Analysis Executive Summary

Dengue vaccines protect against dengue fever, a mosquito-borne disease spreading fast in tropical and warming regions.

Key segments of the dengue Vaccines market include product (Live Attenuated Vaccines and Candidate Vaccines) and age (Children, Adolescents and Adults).

Canada Dengue Vaccines Market Dynamics

Market Growth Drivers

Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the dengue Vaccines market.

Opportunity

New vaccines, rapid tests and public-private funding for neglected diseases give the dengue Vaccines market room to grow, especially in Asia, Africa and Latin America.

Market Restraints

Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the dengue Vaccines market.

Competitive Landscape for Dengue Vaccines Market in Canada

The dengue Vaccines market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Dengue Vaccines Market in Canada

Policy changes and Reimbursement scenario

Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for dengue Vaccines. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in Canada.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Dengue Vaccines right now, from free public sources.

Latest research 165 papers since 2021 (worldwide)

  1. CD8+ T cells and humoral immunity may mitigate the effects of antibody-dependent enhancement: implications for dengue vaccine design. Journal of virology, 2026
  2. Real-world Evidence on dengue vaccine effectiveness: a systematic review of post-licensure evidence and methodological gaps. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases, 2026
  3. Immunological Challenges and Emerging Strategies in Dengue Virus Vaccine Development. Vaccines, 2026
  4. Efficacy, Immunogenicity, Safety, and Evidence Independence of CYD-TDV and TAK-003 Dengue Vaccines in Children and Adolescents: A Systematic Review and Meta-Analysis. Vaccines, 2026
  5. DEVELOPMENT OF A TETRAVALENT DENGUE VACCINE: GUARDRAILS NEEDED. Transactions of the American Clinical and Climatological Association, 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Dengue Vaccines in context

Canada compared

  • Health spending per person: 6,378 US$ per person (2024). World: 1,317 US$ per person (2023).[1]
  • Doctors: 2.82 per 1,000 people (2023). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 20.3% of people (2025). World: 10.4% of people (2025).[3]

Questions, answered with public data

How much research is published on Dengue Vaccines?
PubMed lists 165 papers added since January 2021 that match this market, worldwide.[4]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Dengue Vaccines in Canada? Our analysts can size it for your plan. Talk to us See the public data Measles vaccine for every country, free. Open the Public Health Dashboard

From our blog

Molecular Point-of-Care Tests: Lab Accuracy, Clinic SpeedTB killed 1.23 million people in 2024. WHO now recommends rapid molecular tests first, bringing lab-grade… Antimicrobial Resistance: Why Faster Testing MattersDrug-resistant infections already kill over a million people a year. Faster testing helps doctors pick the… Needleless Connectors: Small Device, Big Infection ImpactNeedleless connectors protect staff from needle injuries, but if not cleaned they can let germs into the…
Back to Catalogue
Keep exploring

Related Pharmaceuticals reports in Canada

See all
Same topic, other categories

Related on vaccines and infectious diseases

See the topic